Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1992 Dec;46(6):587–594. doi: 10.1136/jech.46.6.587

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

G M Ginsberg 1, D Shouval 1
PMCID: PMC1059674  PMID: 1494073

Abstract

STUDY OBJECTIVE--The aim was to estimate the costs and benefits of a nationwide neonatal vaccination campaign against hepatitis B in Israel for the 1990-2034 period. DESIGN--Using morbidity, mortality, utilisation, and cost data from Israeli and international sources, a spreadsheet model was constructed to carry out the cost-benefit analysis. SETTING--The entire State of Israel, an area of intermediate endemicity. PARTICIPANTS--The population of Israel from 1990-2034. MAIN RESULTS--A policy of immunising all Israeli neonates would, for a cost of $13.8 million, reduce the number of cases of hepatitis B during the 1990-2035 period in the cohort from 359,000 to 166,000 and save the nation around $21.5 million in health resources alone, $16.6 million in averted work absences, and a further $0.6 million in averted premature mortality costs. Even when the savings to the health services ($0.6 million) arising from the reduction in hepatocellular carcinoma are excluded, the direct benefit to cost ratio is 1.51/1, still in excess of unity. CONCLUSIONS--The decision to adopt a nationwide neonatal inoculation policy, starting in January 1992, appears to be not only medically but also economically justifiable.

Full text

PDF
587

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler M. W., Belsey E. M., McCutchan J. A., Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1621–1624. doi: 10.1136/bmj.286.6378.1621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arevalo J. A., Washington A. E. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA. 1988 Jan 15;259(3):365–369. [PubMed] [Google Scholar]
  3. Barbara J. A., Howell D. R., Contreras M., Tedder R. S., Briggs M., Sanderson P. J., Wood J., Bevan G. Indications for hepatitis B immunoglobulin for neonates of HBsAg carrier mothers. Br Med J (Clin Res Ed) 1984 Oct 6;289(6449):880–880. doi: 10.1136/bmj.289.6449.880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beasley R. P., Hwang L. Y., Lee G. C., Lan C. C., Roan C. H., Huang F. Y., Chen C. L. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983 Nov 12;2(8359):1099–1102. doi: 10.1016/s0140-6736(83)90624-4. [DOI] [PubMed] [Google Scholar]
  5. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  6. Beasley R. P., Hwang L. Y., Stevens C. E., Lin C. C., Hsieh F. J., Wang K. Y., Sun T. S., Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983 Mar-Apr;3(2):135–141. doi: 10.1002/hep.1840030201. [DOI] [PubMed] [Google Scholar]
  7. Ben-Porath E., Enat R., Gruia M., Satinger Y. [Etiology of acute viral hepatitis in Israel]. Harefuah. 1985 Jun 16;108(12):583–585. [PubMed] [Google Scholar]
  8. Ben-Porath E., Hornstein L., Zeldis J., Nahmias J., Gruia M., Bilgoray B., Satinger Y. Hepatitis B virus infection and liver disease in Ethiopian immigrants to Israel. Hepatology. 1986 Jul-Aug;6(4):662–666. doi: 10.1002/hep.1840060420. [DOI] [PubMed] [Google Scholar]
  9. Chemtob D., Fassberg J., Kalka I., Harlap S., Slater P. E., Ever-Hadani P., Larouze B. Prevention strategy of hepatitis B virus infection among the Ethiopian community in Israel. Isr J Med Sci. 1991 May;27(5):273–277. [PubMed] [Google Scholar]
  10. De Virgiliis S., Frau F., Sanna G., Turco M. P., Figus A. L., Cornacchia G., Cao A. Perinatal hepatitis B virus detection by hepatitis B virus-DNA analysis. Arch Dis Child. 1985 Jan;60(1):56–58. doi: 10.1136/adc.60.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dudley F. J., Scheuer P. J., Sherlock S. Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet. 1972 Dec 30;2(7792):1388–1393. doi: 10.1016/s0140-6736(72)92963-7. [DOI] [PubMed] [Google Scholar]
  12. Egoz N., Naggan L., Feingold A., Bar-Shany S. Prevalence of hepatitis B antigen among army inductees. Isr J Med Sci. 1975 Aug;11(8):777–780. [PubMed] [Google Scholar]
  13. Eliakim M. Epidemiology of viral hepatitis in Israel, 1978. Isr J Med Sci. 1979 Mar;15(3):248–256. [PubMed] [Google Scholar]
  14. Fattal B. [Infectious disease morbidity in Kibbutzim]. Harefuah. 1988 Sep;115(5-6):111–115. [PubMed] [Google Scholar]
  15. Francis D. P., Favero M. S., Maynard J. E. Transmission of hepatitis B virus. Semin Liver Dis. 1981 Feb;1(1):27–32. doi: 10.1055/s-2008-1063927. [DOI] [PubMed] [Google Scholar]
  16. Francis D. P., Hadler S. C., Thompson S. E., Maynard J. E., Ostrow D. G., Altman N., Braff E. H., O'Malley P., Hawkins D., Judson F. N. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med. 1982 Sep;97(3):362–366. doi: 10.7326/0003-4819-97-3-362. [DOI] [PubMed] [Google Scholar]
  17. Franks A. L., Berg C. J., Kane M. A., Browne B. B., Sikes R. K., Elsea W. R., Burton A. H. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med. 1989 Nov 9;321(19):1301–1305. doi: 10.1056/NEJM198911093211905. [DOI] [PubMed] [Google Scholar]
  18. Ganem D. Persistent infection of humans with hepatitis B virus: mechanisms and consequences. Rev Infect Dis. 1982 Sep-Oct;4(5):1026–1047. doi: 10.1093/clinids/4.5.1026. [DOI] [PubMed] [Google Scholar]
  19. Green M. S., Block C., Slater P. E. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis. 1989 May-Jun;11(3):464–469. doi: 10.1093/clinids/11.3.464. [DOI] [PubMed] [Google Scholar]
  20. Greenfield C., Osidiana V., Karayiannis P., Galpin S., Musoke R., Jowett T. P., Mati P., Tukei P. M., Thomas H. C. Perinatal transmission of hepatitis B virus in Kenya: its relation to the presence of serum HBV-DNA and anti-HBe in the mother. J Med Virol. 1986 Jun;19(2):135–142. doi: 10.1002/jmv.1890190205. [DOI] [PubMed] [Google Scholar]
  21. Hadziyannis S. J. Chronic viral hepatitis. Clin Gastroenterol. 1974 May;3(2):391–408. [PubMed] [Google Scholar]
  22. Hepatitis B vaccine. Health and Public Policy Committee, American College of Physicians. Ann Intern Med. 1984 Jan;100(1):149–150. [PubMed] [Google Scholar]
  23. Hwang L. Y., Roggendorf M., Beasley R. P., Deinhardt F. Perinatal transmission of hepatitis B virus: role of maternal HBeAg and anti-HBc IgM. J Med Virol. 1985 Mar;15(3):265–269. doi: 10.1002/jmv.1890150307. [DOI] [PubMed] [Google Scholar]
  24. Jönsson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J. 1987;63 (Suppl 2):27–32. [PubMed] [Google Scholar]
  25. Kark J. D., Bar-Shani S. Hepatitis A antibody in Israel Defence Forces recruits. J Med Virol. 1981;6(4):341–345. doi: 10.1002/jmv.1890060409. [DOI] [PubMed] [Google Scholar]
  26. Krausz Y., Melamed S., Sandler S. G., Eliakim M. A comparative study of hepatitis B and non-B in hospitalized adults in an endemic area. Isr J Med Sci. 1977 Jan;13(1):9–14. [PubMed] [Google Scholar]
  27. Krugman S. The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA. 1982 Apr 9;247(14):2012–2015. [PubMed] [Google Scholar]
  28. Lahaye D., Strauss P., Baleux C., van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet. 1987 Aug 22;2(8556):441–443. doi: 10.1016/s0140-6736(87)90971-8. [DOI] [PubMed] [Google Scholar]
  29. London W. T. Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention. Hum Pathol. 1981 Dec;12(12):1085–1097. doi: 10.1016/s0046-8177(81)80329-2. [DOI] [PubMed] [Google Scholar]
  30. Martini G. A., Strohmeyer G. Posthepatitis syndromes. Clin Gastroenterol. 1974 May;3(2):377–390. [PubMed] [Google Scholar]
  31. Matzkin H. Epidemiological features of acute viral hepatitis among the Israeli Defence Forces, 1977-83. J Infect. 1987 May;14(3):271–278. doi: 10.1016/s0163-4453(87)93610-3. [DOI] [PubMed] [Google Scholar]
  32. Maupas P., Chiron J. P., Barin F., Coursaget P., Goudeau A., Perrin J., Denis F., Mar I. D. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981 Feb 7;1(8215):289–292. doi: 10.1016/s0140-6736(81)91908-5. [DOI] [PubMed] [Google Scholar]
  33. Maupas P., Melnick J. L. Hepatitis B infection and primary liver cancer. Prog Med Virol. 1981;27:1–5. [PubMed] [Google Scholar]
  34. McMahon B. J., Rhoades E. R., Heyward W. L., Tower E., Ritter D., Lanier A. P., Wainwright R. B., Helminiak C. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet. 1987 Nov 14;2(8568):1134–1136. doi: 10.1016/s0140-6736(87)91557-1. [DOI] [PubMed] [Google Scholar]
  35. Mulley A. G., Silverstein M. D., Dienstag J. L. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982 Sep 9;307(11):644–652. doi: 10.1056/NEJM198209093071103. [DOI] [PubMed] [Google Scholar]
  36. Naggan L., Bar-Shany S., Shmuelewitz O., Finzi M., Prywes R. Prevalence of hepatitis B markers (HBsAg and HBsAb) in women screened at time of delivery. Isr J Med Sci. 1980 May;16(5):347–350. [PubMed] [Google Scholar]
  37. Nayak N. C., Dhar A., Sachdeva R., Mittal A., Seth H. N., Sudarsanam D., Reddy B., Wagholikar U. L., Reddy C. R. Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver. Int J Cancer. 1977 Nov 15;20(5):643–654. doi: 10.1002/ijc.2910200502. [DOI] [PubMed] [Google Scholar]
  38. Polakoff S., Tillett H. E. Acute viral hepatitis B: laboratory reports 1975-9. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1881–1882. [PMC free article] [PubMed] [Google Scholar]
  39. Reisler D. M., Brachott D., Mosley J. W. Viral hepatitis in Israel: morbidity and mortality data. Am J Epidemiol. 1970 Jul;92(1):62–72. doi: 10.1093/oxfordjournals.aje.a121180. [DOI] [PubMed] [Google Scholar]
  40. Sandler S. G., Nath N., Biger Y. Seroepidemiology of hepatitis B virus in Israel. Results of a pilot study in Jerusalem. Am J Epidemiol. 1977 Jul;106(1):76–82. doi: 10.1093/oxfordjournals.aje.a112436. [DOI] [PubMed] [Google Scholar]
  41. Sandler S. G., Shouval D., Marcus M., Eliakim M. Type B and non-B viral hepatitis in Jerusalem. Bull World Health Organ. 1976;54(2):193–198. [PMC free article] [PubMed] [Google Scholar]
  42. Shalev E., Bassan H. M. Viral hepatitis during pregnancy in Israel. Int J Gynaecol Obstet. 1982 Feb;20(1):73–78. doi: 10.1016/0020-7292(82)90048-0. [DOI] [PubMed] [Google Scholar]
  43. Shalit M., Tur-Kaspa R., Adler R., Manny N., Shraga S., Morag A., Eliakim M. Non-A, non-B hepatitis not following transfusion: a study of hospital patients in Jerusalem. Isr J Med Sci. 1982 Oct;18(10):986–989. [PubMed] [Google Scholar]
  44. Shany S. B., Naggan L. HBsAG and anti-HBs among Israeli blood donors. Vox Sang. 1976;30(3):191–199. doi: 10.1111/j.1423-0410.1976.tb02812.x. [DOI] [PubMed] [Google Scholar]
  45. Shaw F. E., Jr, Graham D. J., Guess H. A., Milstien J. B., Johnson J. M., Schatz G. C., Hadler S. C., Kuritsky J. N., Hiner E. E., Bregman D. J. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol. 1988 Feb;127(2):337–352. doi: 10.1093/oxfordjournals.aje.a114808. [DOI] [PubMed] [Google Scholar]
  46. Shouval D., Tur-Kaspa R., Adler R., Mani N., Penchas S., Roggendorf M., Frosner G., Eliakim M. Study of 90 hepatitis B surface antigen carriers in Israel. Isr J Med Sci. 1981 Jun;17(6):407–412. [PubMed] [Google Scholar]
  47. Stevens C. E., Toy P. T., Tong M. J., Taylor P. E., Vyas G. N., Nair P. V., Gudavalli M., Krugman S. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA. 1985 Mar 22;253(12):1740–1745. [PubMed] [Google Scholar]
  48. Stewart J. S., Farrow L. J., Clifford R. E., Lamb S. G., Coghill N. F., Lindon R. L., Sanderson I. M., Dodd P. A., Smith H. G., Preece J. W. A three-year survey of viral hepatitis in West London. Q J Med. 1978 Jul;47(187):365–384. [PubMed] [Google Scholar]
  49. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978;24:40–69. [PubMed] [Google Scholar]
  50. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  51. Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]
  52. Thibault G. E., Mulley A. G., Barnett G. O., Goldstein R. L., Reder V. A., Sherman E. L., Skinner E. R. Medical intensive care: indications, interventions, and outcomes. N Engl J Med. 1980 Apr 24;302(17):938–942. doi: 10.1056/NEJM198004243021703. [DOI] [PubMed] [Google Scholar]
  53. Tolsma D. D., Bryan J. A. The economic impact of viral hepatitis in the United States. Public Health Rep. 1976 Jul-Aug;91(4):349–353. [PMC free article] [PubMed] [Google Scholar]
  54. Tur-Kaspa R., Keshet E., Eliakim M., Shouval D. Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers. J Med Virol. 1984;14(1):17–26. doi: 10.1002/jmv.1890140104. [DOI] [PubMed] [Google Scholar]
  55. Wainwright R. B., McMahon B. J., Bulkow L. R., Hall D. B., Fitzgerald M. A., Harpster A. P., Hadler S. C., Lanier A. P., Heyward W. L. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989 Apr 28;261(16):2362–2366. [PubMed] [Google Scholar]
  56. Xu Z. Y., Liu C. B., Francis D. P., Purcell R. H., Gun Z. L., Duan S. C., Chen R. J., Margolis H. S., Huang C. H., Maynard J. E. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics. 1985 Nov;76(5):713–718. [PubMed] [Google Scholar]
  57. Yodfat Y., London W. T., Whitford P., Wax Y. A seroepidemiologic study of hepatitis B in a rural area in Israel. Am J Epidemiol. 1982 Sep;116(3):456–462. doi: 10.1093/oxfordjournals.aje.a113430. [DOI] [PubMed] [Google Scholar]
  58. Zajac B. A., West D. J., McAleer W. J., Scolnick E. M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986 Jul;13 (Suppl A):39–45. doi: 10.1016/s0163-4453(86)92668-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES